阅读说明：本技术 Itpp在制备预防和/或治疗缺血缺氧损伤及肺损伤的药物中的应用 (Application of ITPP (International Teller Patent on Polypropylene) in preparation of medicine for preventing and/or treating ischemia/anoxia injury and lung injury ) 是由 黄沃林 陈新滋 让·马里·莱恩 陈健文 于 2020-06-08 设计创作，主要内容包括：本发明提供了ITPP在制备预防和/或治疗缺血缺氧损伤及肺损伤的药物中的应用,涉及生物医药技术领域。本发明提供的实施例以小鼠和大鼠为实验材料,通过构建小鼠缺血缺氧模型和大鼠肺损伤模型探究ITPP对缺血缺氧及肺损伤的预防或治疗作用。试验证明：ITPP可明显延长大剂量丙异肾上腺素诱导的缺血缺氧小鼠在密闭容器中的存活时间；ITTP可明显改善LPS诱导肺损伤模型大鼠的肺功能、肺系数、右肺湿干重比值、动脉氧含量、血清炎性因子及肺组织病理改变,对肺损伤组织有明显的改善作用。(The invention provides an application of ITPP in preparation of a medicine for preventing and/or treating ischemia-hypoxia injury and lung injury, and relates to the technical field of biological medicines. In the embodiment provided by the invention, mice and rats are taken as experimental materials, and the prevention or treatment effect of ITPP on ischemia, hypoxia and lung injury is explored by constructing a mouse ischemia and hypoxia model and a rat lung injury model. The test proves that: the ITPP can obviously prolong the survival time of a large dose of the isopropylene induced ischemia hypoxia mouse in a closed container; ITTP can obviously improve the lung function, lung coefficient, right lung wet-dry weight ratio, arterial oxygen content, serum inflammatory factor and lung tissue pathological change of LPS induced lung injury model rats, and has obvious improvement effect on lung injury tissues.)

The application of ITPP in preparing a medicament for preventing and/or treating lung injury.

2. The use of claim 1, wherein the lung injury comprises ischemia-hypoxia induced lung injury.

3. The use of claim 1, wherein the lung injury comprises one or more of viral-infected pneumonia, bacterial-infected pneumonia, mycoplasma-infected pneumonia, chlamydia-infected pneumonia, fungal-infected pneumonia, pneumonia caused by chemicals, lung injury caused by pneumoconiosis.

The application of ITPP in preparing the medicine for preventing and/or treating ischemia-hypoxia injury.

5. The use of claim 4, wherein the ischemia-hypoxia injury comprises hypoxia-induced organ injury comprising one or more of a heart, a lung, a liver, and a kidney.

6. A medicament for the prevention and/or treatment of lung injury according to claim 1 or ischemic-hypoxic injury according to claim 4, wherein the medicament comprises ITPP and an excipient.

Application of ITPP in preparing medicament for treating COVID-19.

8. The medicament for treating COVID-19 is characterized by comprising ITPP and auxiliary materials.

Technical Field

The invention belongs to the technical field of biological medicines, and particularly relates to application of ITPP (International Teller Polypropylene) in preparation of a medicine for preventing and/or treating ischemic and anoxic injuries and lung injuries.

Background

People live by oxygen, and the oxygen is sucked from the lung, enters the blood through the capillary vessels and is transmitted to organs or cells of various parts of the body by the blood. The higher the oxygen content in the blood, the better the human metabolism. Hypoxemia can cause insufficient oxygen supply to the body and further cause organ damage.

COVID-19 and its associated symptoms of pulmonary atrophy, fibrosis, etc., lead to dyspnea and, ultimately, death. The treatment of COVID-19 is still in the preliminary stage of research, and the medical problems caused by COVID-19 are very urgent.

Inositol Trispyrophosphate (ITPP) is a compound that has recently entered clinical vision and has the following structural formula:

it has been discovered that ITPP may be used to enhance immune responses and treat hyperproliferative disorders, or to treat obesity-related diseases such as arteriosclerosis, etc. There are no reports of the use of ITPP in COVID-19 therapy.

Disclosure of Invention

In view of the problems in the background art, the invention aims to provide an application of ITPP in preparing a medicament for preventing and/or treating ischemia-hypoxia injury and lung injury. The ITPP is used for increasing the cytoplasm oxygen supply of the milk-feeding animal cells so as to repair human tissues and organs. In particular, the lung function damage caused by the COVID-19 is recovered, thereby gaining the cure hope of patients with the COVID-19.

In order to achieve the above purpose, the invention provides the following technical scheme:

the invention provides application of ITPP in preparation of a medicament for preventing and/or treating lung injury.

Preferably, the lung injury comprises lung injury caused by ischemic hypoxia.

Preferably, the lung injury comprises one or more of viral pneumonia, bacterial pneumonia, mycoplasma pneumonia, chlamydia pneumonia, fungal pneumonia, pneumonia caused by chemical substances, and lung injury caused by pneumoconiosis.

The invention provides an application of ITPP in preparation of a medicine for preventing and/or treating ischemia-hypoxia injury.

Preferably, the ischemia-hypoxia injury comprises hypoxia-induced organ injury, the organ comprising one or more of a heart, a lung, a liver, and a kidney.

The invention provides a medicine for preventing and/or treating lung injury or ischemia and hypoxia injury, which comprises ITPP and auxiliary materials.

The invention provides an application of ITPP in preparing a medicament for treating COVID-19.

The invention provides a medicament for treating COVID-19, which comprises ITPP and auxiliary materials.

The invention provides an application of ITPP in preparing a medicament for preventing and/or treating organ ischemia and hypoxia injury and lung injury. In the embodiment provided by the invention, mice and rats are used as experimental materials, and the prevention or treatment effect of ITPP on related diseases is researched by constructing a mouse ischemia-hypoxia model and a rat lung injury model. The test proves that: the ITPP can obviously prolong the survival time of a large dose of the isopropylene induced ischemia hypoxia mouse in a closed container; ITTP can obviously improve the lung function, lung coefficient, right lung wet-dry weight ratio, arterial oxygen content, serum inflammatory factor and lung tissue pathological change of LPS induced lung injury model rats, and has obvious improvement effect on lung injury tissues.

Drawings

FIG. 1-a is a pathological graph of HE staining in a normal group (. times.200) in the lung injury assay of LPS-induced pneumonia in rats treated with ITTP in example 2;

FIG. 1-b is a graph of the model group HE staining pathology (× 200) in the lung injury assay for LPS-induced pneumonia in rats treated with ITTP in example 2;

FIG. 1-c is a low dose HE staining pathogram (x 200) in the lung injury assay for LPS-induced pneumonia in rats treated with ITTP in example 2;

FIG. 1-d is a medium dose HE staining pathogram (x 200) in the lung injury assay for LPS-induced pneumonia in rats treated with ITTP in example 2;

FIG. 1-e is a pathological graph (X200) of HE staining in the high dose group in the lung injury assay of LPS-induced pneumonia in rats treated with ITTP in example 2.

Detailed Description

The invention provides an application of ITPP in preparing a medicament for preventing and/or treating ischemia and hypoxia injury and lung injury. In the invention, after the ITPP enters the body of a mammal, the oxygen supply of cytoplasm of mammal cells can be increased, and the function of preventing and/or treating ischemia and anoxia injury and lung injury is further realized. In the present invention, the ischemia-hypoxia injury preferably includes hypoxia-induced organ injury, and the organ preferably includes one or more of a heart, a lung, a liver, and a kidney, and more preferably includes a heart or a lung. In the present invention, the lung injury preferably includes lung injury caused by ischemic hypoxia. In the present invention, the lung injury preferably includes one or more of viral infection pneumonia, bacterial infection pneumonia, mycoplasma infection pneumonia, chlamydia infection pneumonia, fungal infection pneumonia, pneumonia caused by chemical substances, and lung injury caused by pneumoconiosis.

In a hypoxia-resistant test of a large-dose isoproterenol-induced ischemia-hypoxia model mouse, ITPP can increase oxygen supply to heart and lung, and can remarkably prolong the survival time of the model mouse in a closed container. In a lung injury model test of rat pneumonia induced by LPS, ITTP can obviously improve the lung function, lung coefficient, right lung wet-dry weight ratio, arterial oxygen content, serum inflammatory factors and lung tissue pathological changes of rats, and is better at a high dose (1 g/kg). The lung/body weight coefficient and the right lung wet to dry weight ratio also indicate that ITPP can repair lung edema caused by damaged lung tissue.

The invention provides a medicine for preventing and/or treating ischemia-hypoxia injury or lung injury, which comprises ITPP and auxiliary materials. The invention does not specially limit the types and the dosage of the auxiliary materials, and the auxiliary materials can be added according to the requirements of different formulations. In the present invention, the dosage form of the drug includes an injectable drug or an oral drug, more preferably an oral drug, and still more preferably an oral aqueous solution. In the present invention, the ITPP is preferably synthesized by a synthesis method described in "l.f. johnson, m.e. tate, CANADIAN jornal OF chemistry. vol.47, 1969", and the raw materials required for the synthesis preferably include: anhydrous calcium chloride (AR), w is not less than 96%, Limited corporation of Szelong scientific corporation; pyridine (AR), w is more than or equal to 99.5%, Guangzhou chemical reagent factory; sodium phytate (AR), w is more than or equal to 98%, Shanghai Yunye Biotech limited; na + exchange resin, 20-50mesh, SIGMA-ALORICH; h + exchange resin, 100-; DCC (AR), w is more than or equal to 99 percent, Innochem company; acetonitrile (AR), w is more than or equal to 99.0%, Guangzhou chemical reagent factory; methanol (AR), w is more than or equal to 99.5 percent, chemical reagents of national drug group, Inc.

The invention provides an application of ITPP in preparing a medicament for treating COVID-19. Respiratory difficulties are caused by pulmonary diseases such as COVID-19 and pneumonia caused by other various viruses, pneumonia caused by gram-negative bacilli, atrophy, pulmonary fibrosis and the like, and finally, the lung is damaged, so that the lung is dead. The invention utilizes ITPP to increase oxygen supply of cells, so that the severely damaged lung organ can recover the function, thereby having the treatment effect on patients with COVID-19.

The invention provides a medicament for treating COVID-19, which comprises ITPP and auxiliary materials. The invention does not specially limit the types and the dosage of the auxiliary materials, and the auxiliary materials are added according to the requirements of different formulations. In the present invention, the dosage form of the drug includes an injectable drug or an oral drug, more preferably an oral drug, and still more preferably an oral aqueous solution. In the present invention, the ITPP is preferably synthesized by the synthesis method described in the document "L.F.JOHNSON, M.E.TATE, CANADIAN JOURNAL OFCHEMISTRY. VOL.47, 1969", and the raw materials required for the synthesis preferably include: anhydrous calcium chloride (AR), w is not less than 96%, Szelong scientific corporation; pyridine (AR), w is more than or equal to 99.5%, Guangzhou chemical reagent factory; sodium phytate (AR), w is more than or equal to 98%, Shanghai Yunye Biotech limited; na + exchange resin, 20-50mesh, SIGMA-ALORICH; h + exchange resin, 100-; DCC (AR), w is more than or equal to 99 percent, Innochem company; acetonitrile (AR), w is not less than 99.0%, Guangzhou chemical reagent factory; methanol (AR), w is more than or equal to 99.5 percent, chemical reagents of national drug group, Inc.

The following examples are provided to illustrate the application of the ITPP of the present invention in the preparation of drugs for preventing and/or treating ischemia-hypoxia injury and lung injury, but they should not be construed as limiting the scope of the present invention.